DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Ionis - 2 Morgan Stanley - 1 Garadacimab - 1 Citi - 1 Russell - 1 Dan Niles - 1 CNBC's - 1 Niles - 1
Top related locs:
Israel Gaza U.S California Tyler Van Buren Bengaluru
Top related orgs:
Citi - 3 Ionis Pharmaceuticals - 3 Biotech - 1 Intellia Therapeutics - 1 CSL - 1 Intellia - 1 CNBC - 1 Russell - 1

Search resuls for: "Ionis Pharmaceutical"


6 mentions found


☆ Citi names 3 biotech stocks to play a growing $2.9 billion opportunity — giving one about 50% upside
  + stars: | 2024-05-01 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +2 min
The outlook is starting to look bright for biotech stocks, according to some. With markets now expecting the first rate cut to be in September rather than June or July, as previously thought, biotech stocks could start to do well. Biotech encompasses many different areas, but Citi has identified one with a $2.9 billion market — which it says is set for even more growth. It gave CSL a price target of $305, or nearly 11% potential upside. It gave Intellia a price target of $31, or 49% potential upside.
Persons: Morgan Stanley, Garadacimab, Ionis, Citi Organizations: Biotech, Citi, Ionis Pharmaceuticals, Intellia Therapeutics, CSL, Intellia
☆ Wall Street says small-cap stocks are a good bet in a choppy market. Here are the top names
  + stars: | 2023-10-17 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +3 min
Small-cap stocks were on investors' radar last week. The Russell 2000 index turned in five straight days of gains for the first time since mid-July, according to CNBC analysis. "We're in consumer staples stocks and Russell 2000 stocks," said Niles, adding that Pepsi is the fourth-largest holding in his Satori Fund's consumer staples basket. Both Citi and Morningstar said small-cap stocks now look cheaper than the broader market. How to play small-caps One of the more popular ways to invest in small-cap stocks is through the iShares Russell 2000 ETF (IWM).
Persons: Russell, Dan Niles, CNBC's, Niles, David Bailin, Morningstar, Davidson, — CNBC's Michelle Fox, Fred Imbert Organizations: CNBC, Russell, Pepsi, Citi, Citi Global Wealth's, Morningstar Equity Research, Ionis Pharmaceuticals, Screen CNBC Pro Locations: Israel, Gaza
☆ This little-known pharma stock can rally 50%, Citi says
  + stars: | 2023-07-31 | by ( Brian Evans | ) www.cnbc.com   time to read: +1 min
It's time to buy shares of Ionis Pharmaceuticals , according to Citi. The firm upgraded the stock on Monday to buy from neutral and raised its price target to $60 from $36. "Though HAE is a competitive market, Phase II data hints that it could have an attractive product profile and be a meaningful player," Lebowitz said. Given current valuation, we view the risk-reward on Ionis shares as being skewed positive." Lebowitz also highlighted donidalorsen's phase 2 test performance, which underpinned the stock upgrade.
Persons: David Lebowitz, eplontersen, HAE, Lebowitz, donidalorsen, Ionis, Michael Bloom Organizations: Ionis Pharmaceuticals, Citi, AstraZeneca, donidalorsen, Ionis
☆ BridgeBio's heart disease drug meets late-stage study goal, shares soar
  + stars: | 2023-07-17 | by ( Khushi Mandowara | ) www.reuters.com   time to read: +2 min
July 17 (Reuters) - BridgeBio Pharma Inc's (BBIO.O) experimental drug for a rare heart disease showed significant improvement in patients in a late-stage study, sending its shares surging 65% on Monday. BridgeBio's drug improved survival by 81% in the study patients compared to 74% on the placebo, and also reduced frequency of heart disease-related hospitalization by 50%. The California-based company also provided additional data comparing it with Pfizer's drug. Acoramidis showed 92% improvement on heart failure test, compared to patients on placebo and Pfizer's drug at 30 months. The additional data suggests that BridgeBio's drug was better than tafamidis in controlling the disease, said TD Cowen analyst Tyler Van Buren.
Persons: acoramidis, Acoramidis, Cowen, Tyler Van, Luca Issi, BridgeBio, BridgeBio's, Khushi, Nivedita Bhattacharjee Organizations: BridgeBio Pharma, Alnylam Pharmaceuticals, Ionis Pharmaceutical, RBC Capital, U.S . Food, Drug Administration, Thomson Locations: U.S, California, Tyler Van Buren, Bengaluru
☆ Morningstar: Buy these 14 cheap stocks that still have room to rally in a bear market
  + stars: | 2022-11-24 | by ( Lisa Kailai Han | ) www.businessinsider.com   time to read: +4 min
Contrary to intutition, bear market rallies may make it tougher for investors to do their jobs. Morningstar shared 14 stocks that are still cheap, despite beating the market. Then, they whittled that list down to the stocks that Morningstar analysts considered undervalued. Finally, Morningstar analysts highlighted AstraZeneca (AZN), noting its strong pipeline and its development of drugs that carry high pricing power. The full list of Morningstar's 14 undervalued bear market stars is below, along with each firm's ticker, sector, bear market return, and price discount.
☆ Wells Fargo says buy small caps over large caps. Here are 10 favorites
  + stars: | 2022-11-08 | by ( Alex Harring | ) www.cnbc.com   time to read: +2 min
Small-cap stocks in Wells Fargo's portfolio are poised to outperform their larger counterparts. "Last year we said small-cap Quality was historically mispriced, but did not think the macro environment favored small caps over large caps," he said in a Monday note to clients. "Going forward, we still believe in a High Quality approach, and we now expect small caps to outpace large caps." Harvey said small caps are technically oversold, but they are beginning to "bounce" while having "more attractive" valuations. The portfolio includes about three dozen stocks that Wells Fargo calls "high quality" small caps.
0 next >>
Total: 6